Biopharmaceutical company Nordic Nanovector ASA (Oslo:NANOV) said on Tuesday that it has entered into a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a potential treatment for patients with B-cell malignancies.
The collaboration aims to combine Nordic Nanovector's expertise around CD37, a protein present on the surface of B-cell tumour cells, with the US university's expertise in CAR-T cell therapies.
Researchers at the University of Pennsylvania (Penn) will look to combine CD37-targeting molecules (antibodies and antibody fragments) and linkers provided by Nordic Nanovector, with the proprietary CAR-T technologies developed at Penn that can direct CAR-T cells against multiple tumour associated antigens.
Nordic Nanovector has obtained an option to license exclusive worldwide rights to any CD37-targeting CAR-T cells that result from this collaboration for further development.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study